Information letter addressed to healthcare professionals regarding the medicinal product Epadol Neo (omega-3 acid ethyl esters): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular disease or cardiovascular risk factors

25.12.2025 347 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я, щодо лікарського засобу Епадол Нео (етилові ефіри омега-3-кислот): дозозалежне підвищення ризику розвитку фібриляції передсердь у пацієнтів із встановленими серцево-судинними захворюваннями або серцево-судинними факторами ризикуPDF · 369 КБ

Завантажити

Information letter addressed to healthcare professionals regarding the medicinal product Epadol Neo (omega-3 acid ethyl esters): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular disease or cardiovascular risk factors

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter addressed to healthcare professionals regarding the medicinal product Epadol Neo (omega-3 acid ethyl esters): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular disease or cardiovascular risk factors

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration